Gastrointestinal carcinoid: Epidemiological and survival evidence from a large population-based study (n = 25 531)

Annals of Oncology

Volumn 24, Issue 12, 2013, Pages 3040-3044

  Mocellin, S ^a   Nitti, D ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Carcinoid; Epidemiology; Gastrointestinal; Population based study; SEER; Survival analysis

Indexed keywords

ADULT; ARTICLE; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER REGISTRY; CARCINOID; CUTANEOUS MELANOMA; DIGESTIVE SYSTEM CANCER; DISEASE SPECIFIC SURVIVAL; FEMALE; GASTROINTESTINAL CARCINOID; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NOMOGRAM; POPULATION RESEARCH; PRIORITY JOURNAL; STANDARDIZED INCIDENCE RATIO; SURVIVAL PREDICTION; SURVIVAL RATE;

CARCINOID; EPIDEMIOLOGY; GASTROINTESTINAL; POPULATION-BASED STUDY; SEER; SURVIVAL ANALYSIS;

CARCINOID TUMOR; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RISK; SEER PROGRAM;

EID: 84888786950     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt377     Document Type: Article

References (40)

1. Modlin IM, Oberg K, Chung DC et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008; 9(1): 61-72.
2. Pinchot SN, Holen K, Sippel RS et al. Carcinoid tumors. Oncologist 2008; 13(12):1255-1269.
3. Moran CA, Suster S. Neuroendocrine carcinomas (carcinoid, atypical carcinoid, small cell carcinoma, and large cell neuroendocrine carcinoma): current concepts. Hematol Oncol Clin North Am 2007; 21(3): 395-407; vii.
4. Frilling A, Akerstrom G, Falconi M et al. Neuroendocrine tumor disease: an evolving landscape. Endocr Relat Cancer 2012; 19(5): R163-R185.
5. Modlin IM, Kidd M, Latich I et al. Current status of gastrointestinal carcinoids. Gastroenterology 2005; 128(6): 1717-1751.
6. Kloppel G, Anlauf M. Epidemiology, tumour biology and histopathological classification of neuroendocrine tumours of the gastrointestinal tract. Best Pract Res Clin Gastroenterol 2005; 19(4): 507-517.
7. Dierdorf SF. Carcinoid tumor and carcinoid syndrome. Curr Opin Anaesthesiol 2003; 16(3): 343-347.
8. Gaur P, Sceusi EL, Samuel S et al. Identification of cancer stem cells in human gastrointestinal carcinoid and neuroendocrine tumors. Gastroenterology 2011; 141(5): 1728-1737.
9. Zikusoka MN, Kidd M, Eick G et al. The molecular genetics of gastroenteropancreatic neuroendocrine tumors. Cancer 2005; 104(11):2292-2309.
10. Woodside KJ, Townsend CM, Jr, Mark Evers B. Current management of gastrointestinal carcinoid tumors. J Gastrointest Surg 2004; 8(6): 742-756.
11. Paulson AS, Bergsland EK. Systemic therapy for advanced carcinoid tumors:where do we go from here? J Natl Compr Canc Netw 2012; 10(6): 785-793.
12. Toumpanakis C, Caplin ME. Update on the role of somatostatin analogs for the treatment of patients with gastroenteropancreatic neuroendocrine tumors. Semin Oncol 2013; 40(1): 56-68.
13. PubMed. http://www.ncbi.nlm.nih.gov/pubmed/?Term=carcinoid. 2013.
14. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003; 97(4): 934-959.
15. Ellis L, Shale MJ, Coleman MP. Carcinoid tumors of the gastrointestinal tract:trends in incidence in England since 1971. Am J Gastroenterol 2010; 105(12):2563-2569.
16. Crocetti E, Paci E. Malignant carcinoids in the USA, SEER 1992-1999. An epidemiological study with 6830 cases. Eur J Cancer Prev 2003; 12(3):191-194.
17. Yao JC, Hassan M, Phan A et al. One hundred years after 'carcinoid':epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26(18): 3063-3072.
18. Hodgson N, Koniaris LG, Livingstone AS et al. Gastric carcinoids: a temporal increase with proton pump introduction. Surg Endosc 2005; 19(12): 1610-1612.
19. Thomas D, Tsolakis AV, Grozinsky-Glasberg S et al. Long-term follow-up of a large series of patients with type 1 gastric carcinoid tumors: data from a multicenter study. Eur J Endocrinol 2013; 168(2): 185-193.
20. Gladdy RA, Strong VE, Coit D et al. Defining surgical indications for type I gastric carcinoid tumor. Ann Surg Oncol 2009; 16(11): 3154-3160.
21. Landry CS, McMasters KM, Scoggins CR et al. Proposed staging system for gastrointestinal carcinoid tumors. Am Surg 2008; 74(5): 418-422.
22. Curran T, Tulin-Silver S, Patel K et al. Prognostic clinicopathologic factors in longitudinally followed patients with metastatic small bowel carcinoid tumors. Pancreas 2011; 40(8): 1253-1257.
23. Landerholm K, Zar N, Andersson RE et al. Survival and prognostic factors in patients with small bowel carcinoid tumour. Br J Surg 2011; 98(11): 1617-1624.
24. Karatzas G, Kouskos E, Kouraklis G et al. Gastrointestinal carcinoid tumors: 10-year experience of a general surgical department. Int Surg 2004; 89(1): 21-26.
25. Van Gompel JJ, Sippel RS, Warner TF et al. Gastrointestinal carcinoid tumors:factors that predict outcome. World J Surg 2004; 28(4): 387-392.
26. Maggard MA, O'Connell JB, Ko CY. Updated population-based review of carcinoid tumors. Ann Surg 2004; 240(1): 117-122.
27. Tsikitis VL, Wertheim BC, Guerrero MA. Trends of incidence and survival of gastrointestinal neuroendocrine tumors in the United States: a seer analysis. J Cancer 2012; 3: 292-302.
28. Landry CS, Brock G, Scoggins CR et al. A proposed staging system for gastric carcinoid tumors based on an analysis of 1,543 patients. Ann Surg Oncol 2009; 16(1): 51-60.
29. Landry CS, Brock G, Scoggins CR et al. A proposed staging system for rectal carcinoid tumors based on an analysis of 4701 patients. Surgery 2008; 144(3):460-466.
30. Modlin IM, Gustafsson BI, Pavel M et al. A nomogram to assess small-intestinal neuroendocrine tumor ('carcinoid') survival. Neuroendocrinology 2010; 92(3):143-157.
31. Mullen JT, Savarese DM. Carcinoid tumors of the appendix: a population-based study. J Surg Oncol 2011; 104(1): 41-44.
32. SEER. SEER*Stat Database: Incidence-SEER 18 Regs Limited-Use + Hurricane Katrina Impacted Louisiana Cases, Nov 2011 Submission (1973-2009 varying):USA: National Cancer Institute, 2011.
33. SEER. Surveillance Research Program, SEER*Stat software version 8.0.2. USA:National Cancer Institute, 2013.
34. Grambsch TM, Therneau M. Modelling Survival Data. New York: Springer, 2000.
35. Harrell FE, Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15(4): 361-387.
36. Sauerbrei W, Royston P, Binder H. Selection of important variables and determination of functional form for continuous predictors in multivariable model building. Stat Med 2007; 26(30): 5512-5528.
37. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62(1): 10-29.
38. Ferlay J, Shin HR, Bray F et al. Estimates of worldwide burden of cancer in 2008:GLOBOCAN 2008. Int J Cancer 2010; 127(12): 2893-2917.
39. Mocellin S, Nitti D. Cutaneous melanoma in situ: translational evidence from a large population-based study. Oncologist 2011; 16(6): 896-903.
40. Mocellin S, Verdi D, Pooley KA et al. Telomerase reverse transcriptase locus polymorphisms and cancer risk: a field synopsis and meta-analysis. J Natl Cancer Inst 2012; 104(11): 840-854.